

1 **A common androgen synthesis variant is associated with COVID susceptibility**

2

3

4 **Authors:** Jeffrey M. McManus<sup>1</sup>, Navin Sabharwal<sup>1</sup>, Peter Bazeley<sup>2</sup> and Nima Sharifi<sup>1,3,4\*</sup>

5

6 **Affiliations:**

7 <sup>1</sup>Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic,  
8 Cleveland, Ohio, USA.

9 <sup>2</sup>Center for Clinical Genomics, Genomics Medicine Institute, Cleveland Clinic, Cleveland, Ohio,  
10 USA.

11 <sup>3</sup>Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland,  
12 Ohio, USA.

13 <sup>4</sup>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland,  
14 Ohio, USA.

15 \*Corresponding author

16 Email: [sharifn@ccf.org](mailto:sharifn@ccf.org)

17

18

19

20

21

## 22 Summary Paragraph

23 A sex discordance in COVID exists, with males disproportionately affected<sup>1-3</sup>. More  
24 broadly, sex differences in infectious and inflammatory processes are well known, with women  
25 tending to mount stronger immune responses than men<sup>4,5</sup>. Although there is evidence that sex  
26 hormone signaling is immunomodulatory<sup>6-8</sup>, including downregulation of immune/inflammatory  
27 responses by androgens<sup>9</sup>, the existence of numerous other physiologic differences between the  
28 sexes leads to great uncertainty in attributing worse infectious disease outcomes in men to  
29 androgen signaling. No definitive genetic data exist to support androgen-mediated immune  
30 suppression for viral susceptibility, nor for adrenal androgens. Here we show an association  
31 between inheritance of the common adrenal-permissive missense-encoding variant  
32 *HSD3BI*(1245C), that enables androgen synthesis from adrenal precursors<sup>10</sup>, and susceptibility to  
33 COVID. The adrenal-permissive *HSD3BI*(1245C) has previously been linked to suppression of  
34 inflammation in severe asthma<sup>11</sup>. In analysis of COVID test results from the UK Biobank, we show  
35 that in older ( $\geq 70$  years of age) subjects, the adrenal-permissive variant is associated with a greater  
36 chance of being COVID-positive. The effect increases with the number of *HSD3BI*(1245C) alleles  
37 inherited and is greater in females such that increasing androgen synthesis confers risk approaching  
38 males. Our study suggests that a common androgen synthesis variant regulates immune  
39 susceptibility to COVID infection as well as potentially other immune and inflammatory processes.  
40

41 **Main Text**

42

43 **Introduction**

44 The COVID-19 pandemic caused by the SARS-CoV-2 virus emerged in late 2019 and in  
45 the early months of 2020 quickly became a global health emergency. Recognition that men face  
46 higher risks of hospitalization and death from COVID than women<sup>1-3</sup> has spurred research into  
47 whether sex hormone signaling plays a role in COVID susceptibility and/or outcomes. Although  
48 much of this research has focused on whether androgens regulate viral receptor protein ACE2 and  
49 co-receptor TMPRSS2<sup>12-15</sup>, it is also known that sex hormone signaling can modulate immune  
50 responses<sup>6-8</sup>. Generally speaking, a sex discordance in inflammatory and infectious disease  
51 processes<sup>4,5</sup>, including COVID, is recognized. However, there is great uncertainty in attributing  
52 the difference in outcomes to androgens because there are many other physiologic differences that  
53 exist between males and females.

54 The enzyme 3 $\beta$ -hydroxysteroid dehydrogenase isotype 1 (3 $\beta$ HSD1) catalyzes a critical and  
55 rate-limiting step in the pathway to production in peripheral tissues of the potent androgens  
56 testosterone and dihydrotestosterone (DHT) from adrenally produced precursors  
57 dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S<sup>10</sup>. The adrenal-permissive form  
58 of the gene for 3 $\beta$ HSD1, *HSD3B1*(1245C), that was originally linked to faster prostate cancer  
59 progression in the face of androgen deprivation therapy (i.e., medical castration) because of  
60 adrenally derived androgen synthesis<sup>16-21</sup>, has more recently been shown to also affect the response  
61 to oral glucocorticoid treatment in patients with severe asthma<sup>11</sup>. The 1245C, or adrenal-permissive  
62 allele, encodes a form of the enzyme that is resistant to ubiquitination and degradation, thus leading  
63 to increased production of potent androgens from adrenal precursors. By contrast, the 1245A, or

64 adrenal-restrictive allele, encodes a more rapidly degraded form of the enzyme, leading to less  
65 production of potent androgens<sup>22</sup>. A side effect of glucocorticoid treatment is suppression of  
66 circulating DHEA and DHEA-S levels<sup>11</sup>. Active androgens (i.e., potent agonists of the androgen  
67 receptor) testosterone and DHT are thought to downregulate immune/inflammatory responses<sup>9</sup>.  
68 Thus, even in an environment of a decreased adrenal precursor pool brought on by glucocorticoid  
69 treatment, the adrenal-permissive 1245C allele still enables sufficient downstream androgen  
70 production to reduce airway inflammation in those with severe asthma, whereas patients with the  
71 adrenal-restrictive 1245A allele experience less reduction in airway inflammation<sup>11</sup> (**Fig. 1**).

72 The frequency of the C allele varies enormously across different racial and ethnic groups  
73 and is highest among Europeans, particularly in Southern Europe<sup>23,24</sup>. Early in the COVID-19  
74 pandemic, two of the worst outbreaks occurred in Italy and Spain, countries among those with the  
75 highest 1245C allele frequencies. This, in conjunction with the evidence from cohorts of severe  
76 asthmatics that *HSD3B1* genotype could affect immune responses, led us to ask whether there are  
77 links between *HSD3B1* genotype and COVID susceptibility and/or outcomes. Additionally, in both  
78 prostate cancer and asthma, the effect of the adrenal-permissive allele becomes evident specifically  
79 in contexts of decreased circulating androgen levels due to androgen deprivation therapy in  
80 prostate cancer and glucocorticoid treatment in asthma. Circulating androgen levels decline with  
81 age<sup>25-27</sup>, so as COVID most severely impacts older patients<sup>2,28</sup>, this provided further impetus for  
82 determining whether a link exists between *HSD3B1* and COVID.

83

## 84 **Results**

85 To examine whether COVID susceptibility and *HSD3B1* genotype are associated, we  
86 performed regression analyses between presence of a positive COVID test result and genotype in

87 COVID-tested subjects of the UK Biobank Caucasian cohort; UK Biobank subjects of other races  
88 were excluded due to inadequate sample sizes and lower frequency of the 1245C allele. The UK  
89 Biobank is a long-term study containing genotyping results and detailed medical information from  
90 approximately 500,000 UK residents who were between the ages of 40 and 69 years when recruited  
91 to the study in 2006-2010<sup>29</sup>. Current ages range from 50 to 83 with a median age of 70. As of  
92 August 3, 2020, COVID test results had been reported for 10,061 Caucasian UK Biobank subjects,  
93 1,148 having tested positive.

94 We performed logistic regressions and calculated odds ratios including both a regression  
95 against the number (0, 1, or 2) of adrenal-permissive *HSD3B1* 1245C alleles and a comparison of  
96 homozygous 1245C (CC) genotype to the combined pool of AA and AC genotypes. We analyzed  
97 men and women of all ages together as well as men and women separately, and to determine  
98 whether there is an association specific to those of advanced age, we further broke these groups  
99 down according to age below 70 (the median age of the overall cohort) and age 70 or above. The  
100 results (**Table 1, Fig. 2a**) show COVID positivity is associated with CC genotype in subjects of  
101 age 70 or above (OR = 1.30, 95% CI = 1.01 – 1.68) and that this association appears to be more  
102 pronounced in women (OR = 1.49, 95% CI = 1.02 – 2.16) than in men (OR = 1.20, 95% CI = 0.85  
103 – 1.69).

104 To test whether the association in subjects of elevated age might be due to selecting a cutoff  
105 age that happened to create the strongest result, we systematically varied the lower cutoff age for  
106 inclusion in the regression analysis from 50 (i.e., no exclusions due to age) through 80 and  
107 calculated the odds ratios and confidence intervals by year of cutoff age. **Figure 3** shows the results  
108 for women: for each year of age, the odds ratio and confidence interval for COVID positivity  
109 among women of that age or older are shown. Because results similar to our initial cutoff were

110 obtained over a wide range of cutoff ages, the association in subjects of elevated age is not the  
111 result of having selected a specific age. As the cutoff age increases, the odds ratio tends to become  
112 larger; at the same time, the confidence interval grows wider as the sample size decreases due to  
113 the more restrictive age cutoff (e.g., at a cutoff age of 70, subjects of age 70-83 are included; at a  
114 cutoff age of 80, only subjects of age 80-83 are included). Similar results but with lower odds  
115 ratios were obtained for men and women together (**Fig. S1a**). For men alone, the shape of the  
116 graph is similar, but the lower bound of the confidence interval only reaches 1 for a limited range  
117 of cutoff ages above 75 (**Fig. S1b**), suggesting the possibility that older men's COVID positivity  
118 associates with CC genotype in a way similar to older women's but less strongly.

119 We additionally observed that when looking at all genotypes together, men had a higher  
120 positive test rate than women (men: 12.3% positive, 95% CI = 11.4% - 13.2%; women: 10.5%  
121 positive, 95% CI = 9.7% - 11.3%). However, women with the CC genotype had a similar positive  
122 rate to the overall male positive rate (12.5%, 95% CI = 9.7% - 15.3%). Specifically, in women at  
123 least 70 years of age, the positive rate appeared to increase in a stepwise fashion with the number  
124 of C alleles: 0 C alleles, 7.9% (95% CI = 6.4% - 9.4%); 1 C allele, 9.2% (95% CI = 7.5% - 10.9%);  
125 2 C alleles, 12.2% (95% CI = 8.5% - 15.9%).

126 Having found that *HSD3B1* genotype is associated with the rate of COVID positivity, we  
127 next performed the same analysis but on the entire UK Biobank Caucasian cohort rather than just  
128 those who had COVID test results. We compared those who had tested positive for COVID to all  
129 other members of the cohort, including analyses with the same breakdowns by sex and age. The  
130 results (**Table S1, Fig. 2b**) are very similar to the results when analyzing only those who were  
131 COVID-tested. Again, there is an association between COVID positivity and CC genotype in  
132 subjects of age 70 or above (OR = 1.30, 95% CI = 1.03 – 1.65), and this association appears to be

133 more pronounced in women (OR = 1.55, 95% CI 1.09 – 2.20) than in men (OR = 1.14, 95% CI  
134 0.83 – 1.57).

135 We next analyzed the UK Biobank’s death records to test for associations between COVID  
136 as a cause of death and *HSD3B1* genotype. We again analyzed the entire Caucasian cohort, men  
137 and women separately, and these same groups restricted to those at least 70 years of age. Analyses  
138 limited to those under 70 years of age were not included because the number of deaths was very  
139 small among those under 70. Although no associations reached the  $p = 0.05$  level (**Table S2**), we  
140 did observe a trend toward higher risk of COVID death in women of CC genotype but not in men,  
141 and the strongest trend was in women at least 70 years of age with the CC genotype (OR 1.60, 95%  
142 CI 0.92 – 2.77). It should be noted that the set of COVID deaths only partly overlaps the set of  
143 COVID-positive cases from the previous analyses: of 325 total COVID deaths, 200 were people  
144 who had tested positive for COVID, 110 were people who had no COVID test results reported,  
145 and 15 were people who had only negative COVID test results reported.

146 We also analyzed associations between all-cause mortality and *HSD3B1* genotype among  
147 only those subjects of the UK Biobank Caucasian cohort with positive COVID test results (**Table**  
148 **S3**). This analysis contained the smallest sample sizes, and again no associations reached the  $p =$   
149  $0.05$  level. However, it was striking that, as with all the previous analyses of both COVID  
150 susceptibility and COVID mortality, the largest association was observed in women at least 70  
151 years of age with the CC genotype (OR 1.59, 95% CI 0.74 – 3.41).

152

## 153 **Discussion**

154 We have demonstrated that, in the UK Biobank Caucasian cohort, there is an association  
155 between possessing two copies of the adrenal-permissive *HSD3B1* 1245C allele and testing

156 positive for COVID-19 in subjects age 70 or older, and the size of the effect becomes larger when  
157 looking specifically at women age 70 or older. This association exists whether comparing those  
158 subjects who tested positive to those who tested negative (**Table 1, Fig. 2A**) or comparing those  
159 subjects who tested positive to all other members of the population (**Table S1, Fig. 2B**). This  
160 association in older women is not an artifact of having selected a specific cutoff age, but rather is  
161 present over a wide range of cutoff ages (**Figure 3**). A similar but weaker effect may be present in  
162 older men with the CC genotype (**Figure S1**).

163 It may be seen as surprising that results were so similar when comparing COVID-positive  
164 subjects to COVID-negative subjects as when comparing positive subjects to all other subjects, as  
165 one might assume that the pool of non-tested subjects would contain both COVID-positive and -  
166 negative subjects, and would therefore fall between the COVID-positive pool and the COVID-  
167 negative pool. However, considering that there is a substantial false-negative rate in COVID  
168 testing<sup>30</sup>, and that someone who has been tested for COVID would *a priori* be more likely to have  
169 been infected with COVID than a random member of the population, this similarity becomes less  
170 surprising.

171 Previously reported phenotypic associations with adrenal-restrictive vs. adrenal-permissive  
172 *HSD3B1* genotype, in both prostate cancer and asthma, occur in contexts of reduced circulating  
173 androgen levels. Circulating androgen levels, including levels of the adrenally produced precursor  
174 DHEA that is a  $3\beta$ HSD1 substrate in the pathway to potent androgen production, decrease with  
175 increasing age in both sexes, which is in line with the association we observed specifically in  
176 subjects of advanced age. Furthermore, in men, the pool of gonadally produced androgens is vastly  
177 larger than in women; therefore, the relative contribution of adrenally produced androgens is  
178 greater in women, in line with the association with adrenal-permissive androgen synthesis being

179 stronger in women. As COVID outcomes are by far the worst in elderly patients, the existence of  
180 a germline steroid-metabolizing enzyme variant that makes older people more susceptible to  
181 COVID is of physiologic and potentially pharmacologic importance. Intriguingly, whereas the  
182 overall higher positive rate we observed in men compared to women aligns with the well-known  
183 existence of greater rates of severe COVID and COVID death among men, when looking  
184 specifically at women of CC genotype, the positive rate reached the overall positive rate in men,  
185 genetically supporting the androgen association.

186 The results on COVID mortality in this cohort are based on relatively small sample sizes  
187 and must be considered preliminary, but it is striking that, as with both methods of analyzing  
188 association with COVID positivity (**Table 1** and **Table S1**), the largest associations with COVID  
189 mortality among all UK Biobank Caucasian subjects (**Table S2**) and with mortality among  
190 COVID-positive UK Biobank Caucasian subjects (**Table S3**) were in women of CC genotype age  
191 70 or older. If these associations are real, an association with COVID mortality among women in  
192 general could be simply a consequence of the association with COVID susceptibility, whereas an  
193 association with mortality among COVID-positive women would imply that the CC genotype also  
194 leads to worse outcomes among infected women. It should, however, be noted that the latter  
195 association has the smallest sample size and weakest statistical support.

196 Although our interrogation of these associations was originally inspired in part by severe  
197 COVID outbreaks in countries like Italy and Spain whose populations have high germline  
198 frequencies of the adrenal-permissive 1245C allele, it is also the case that higher rates of COVID  
199 infection and death have occurred in the United States among people of African descent<sup>31,32</sup>, a  
200 population with much lower 1245C allele frequencies than Caucasians (C allele frequencies in the  
201 UK Biobank: African 0.085, Caucasian 0.323, consistent with results reported elsewhere<sup>23</sup>).

202 Therefore, although possessing the adrenal-permissive allele might affect an individual person's  
203 COVID susceptibility, many other genetic and socioeconomic factors must be considered and are  
204 confounding across different races and ethnicities.

205         It was recently shown in a large, randomized trial that treatment with the glucocorticoid  
206 dexamethasone strongly reduced mortality in COVID patients on ventilation but not in patients  
207 receiving no respiratory support<sup>33</sup>. Taken together with the findings we report here and our  
208 previous finding that *HSD3B1* genotype affects response to glucocorticoid treatment in asthma  
209 with the adrenal-permissive 1245C allele associated with reduced airway inflammation<sup>11</sup>, this  
210 raises the question of whether *HSD3B1* genotype could affect response to dexamethasone in  
211 COVID patients. The differential effects of dexamethasone in patients who were or were not  
212 receiving respiratory support also highlights how the results of steroid-induced immune  
213 suppression could be context-dependent: immune suppression could make it harder to ward off an  
214 initial infection, but could be beneficial in a patient with an advanced infection and out-of-control  
215 inflammatory response.

216         All the results reported here require validation from an independent cohort. If this  
217 validation is forthcoming, it would be an important finding in both the field of COVID research as  
218 well as in the broader area of the role of sex hormones in immune responses. Importantly, the  
219 existence of a differential immune response based on differential androgen metabolism occurring  
220 specifically within one sex (i.e., women) could help shed light on the role of androgens in immune  
221 responses in general. Comparisons between men (higher androgen levels) and women (lower  
222 androgen levels) are confounded by numerous other physiologic differences between the sexes; in  
223 a comparison between women with adrenal-permissive and women with adrenal-restrictive  
224 androgen synthesis, these confounding factors are absent. The mechanisms by which inherited

225 adrenal androgen metabolism by way of *HSD3B1* genotype affects immune responses are subjects  
226 for future study.

227

## 228 **References**

229

230 1 Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how  
231 biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews*  
232 *Immunology* **20**, 442-447, doi:10.1038/s41577-020-0348-8 (2020).

233 2 Palaiodimos, L. *et al.* Severe obesity, increasing age and male sex are independently  
234 associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of  
235 patients with COVID-19 in the Bronx, New York. *Metabolism* **108**, 154262-154262,  
236 doi:10.1016/j.metabol.2020.154262 (2020).

237 3 Michelozzi, P. *et al.* Mortality impacts of the coronavirus disease (COVID-19) outbreak by  
238 sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020.  
239 *Eurosurveillance* **25**, 2000620, doi:doi:[https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.19.2000620)  
240 [7917.ES.2020.25.19.2000620](https://doi.org/10.2807/1560-7917.ES.2020.25.19.2000620) (2020).

241 4 Fischer, J., Jung, N., Robinson, N. & Lehmann, C. Sex differences in immune responses to  
242 infectious diseases. *Infection* **43**, 399-403, doi:10.1007/s15010-015-0791-9 (2015).

243 5 Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nature reviews.*  
244 *Immunology* **16**, 626-638, doi:10.1038/nri.2016.90 (2016).

245 6 Bouman, A., Heineman, M. J. & Faas, M. M. Sex hormones and the immune response in  
246 humans. *Human Reproduction Update* **11**, 411-423, doi:10.1093/humupd/dmi008 (2005).

- 247 7 Foo, Y. Z., Nakagawa, S., Rhodes, G. & Simmons, L. W. The effects of sex hormones on  
248 immune function: a meta-analysis. *Biological Reviews* **92**, 551-571, doi:10.1111/brv.12243  
249 (2017).
- 250 8 Taneja, V. Sex Hormones Determine Immune Response. *Frontiers in Immunology* **9**,  
251 doi:10.3389/fimmu.2018.01931 (2018).
- 252 9 Gubbels Bupp, M. R. & Jorgensen, T. N. Androgen-Induced Immunosuppression.  
253 *Frontiers in Immunology* **9**, doi:10.3389/fimmu.2018.00794 (2018).
- 254 10 Naelitz, B. D. & Sharifi, N. Through the Looking-Glass: Reevaluating DHEA Metabolism  
255 Through HSD3B1 Genetics. *Trends Endocrinol Metab*, doi:10.1016/j.tem.2020.05.006  
256 (2020).
- 257 11 Zein, J. *et al.* HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma.  
258 *Proceedings of the National Academy of Sciences* **117**, 2187-2193,  
259 doi:10.1073/pnas.1918819117 (2020).
- 260 12 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is  
261 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278,  
262 doi:<https://doi.org/10.1016/j.cell.2020.02.052> (2020).
- 263 13 Mjaess, G., Karam, A., Aoun, F., Albisinni, S. & Roumeguère, T. COVID-19 and the male  
264 susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. *Progrès en*  
265 *Urologie*, doi:<https://doi.org/10.1016/j.purol.2020.05.007> (2020).
- 266 14 Sharifi, N. & Ryan, C. J. Androgen hazards with COVID-19. *Endocrine-related cancer* **27**,  
267 E1-e3, doi:10.1530/erc-20-0133 (2020).

- 268 15 Song, H., Seddighzadeh, B., Cooperberg, M. R. & Huang, F. W. Expression of ACE2, the  
269 SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. *Eur Urol* **78**, 296-298,  
270 doi:10.1016/j.eururo.2020.04.065 (2020).
- 271 16 Hearn, J. W. D. *et al.* HSD3B1 and resistance to androgen-deprivation therapy in prostate  
272 cancer: a retrospective, multicohort study. *Lancet Oncol* **17**, 1435-1444,  
273 doi:10.1016/S1470-2045(16)30227-3 (2016).
- 274 17 Agarwal, N. *et al.* Independent Validation of Effect of HSD3B1 Genotype on Response to  
275 Androgen-Deprivation Therapy in Prostate Cancer. *JAMA Oncol*,  
276 doi:10.1001/jamaoncol.2017.0147 (2017).
- 277 18 Shiota, M. *et al.* Association of Missense Polymorphism in HSD3B1 With Outcomes  
278 Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or  
279 Abiraterone. *JAMA Netw Open* **2**, e190115, doi:10.1001/jamanetworkopen.2019.0115  
280 (2019).
- 281 19 Garcia Gil, S., Ramos Rodriguez, R., Plata Bello, A., Nazco Casariego, G.J., Garcia  
282 Marrero, R., Cruz Jurado, J., Batista Lopez, J.N., Gonzalez Garcia, J., Gutierrez Nicolas,  
283 F. in *European Society of Oncology Pharmacy* (Nantes, France, 2018).
- 284 20 Hearn, J. W. D. *et al.* Association of HSD3B1 Genotype With Response to Androgen-  
285 Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized  
286 Prostate Cancer. *JAMA Oncol* **4**, 558-562, doi:10.1001/jamaoncol.2017.3164 (2018).
- 287 21 Hearn, J. W. D. *et al.* HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-  
288 Sensitive Prostate Cancer. *JAMA Oncology* **6**, e196496-e196496,  
289 doi:10.1001/jamaoncol.2019.6496 (2020).

- 290 22 Chang, K. H. *et al.* A gain-of-function mutation in DHT synthesis in castration-resistant  
291 prostate cancer. *Cell* **154**, 1074-1084, doi:10.1016/j.cell.2013.07.029 (2013).
- 292 23 Sabharwal, N. & Sharifi, N. HSD3B1 Genotypes Conferring Adrenal-Restrictive and  
293 Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. *Endocrinology* **160**, 2180-  
294 2188, doi:10.1210/en.2019-00366 (2019).
- 295 24 *IGSR: The International Genome Sample Resource. Genome browsers.*  
296 [<https://www.internationalgenome.org/1000-genomes-browsers/>](https://www.internationalgenome.org/1000-genomes-browsers/) (Accessed 11 August  
297 2020)
- 298 25 Laughlin, G. A. & Barrett-Connor, E. Sexual Dimorphism in the Influence of Advanced  
299 Aging on Adrenal Hormone Levels: The Rancho Bernardo Study1. *The Journal of Clinical*  
300 *Endocrinology & Metabolism* **85**, 3561-3568, doi:10.1210/jcem.85.10.6861 (2000).
- 301 26 Muller, M., den Tonkelaar, I., Thijssen, J. H., Grobbee, D. E. & van der Schouw, Y. T.  
302 Endogenous sex hormones in men aged 40-80 years. *European journal of endocrinology*  
303 **149**, 583-589, doi:10.1530/eje.0.1490583 (2003).
- 304 27 Horstman, A. M., Dillon, E. L., Urban, R. J. & Sheffield-Moore, M. The Role of Androgens  
305 and Estrogens on Healthy Aging and Longevity. *The Journals of Gerontology: Series A* **67**,  
306 1140-1152, doi:10.1093/gerona/gls068 (2012).
- 307 28 Du, R.-H. *et al.* Predictors of mortality for patients with COVID-19 pneumonia caused by  
308 SARS-CoV-2: a prospective cohort study. *The European respiratory journal* **55**, 2000524,  
309 doi:10.1183/13993003.00524-2020 (2020).
- 310 29 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.  
311 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).

- 312 30 Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in False-  
313 Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2  
314 Tests by Time Since Exposure. *Annals of internal medicine*, M20-1495, doi:10.7326/M20-  
315 1495 (2020).
- 316 31 Webb Hooper, M., Nápoles, A. M. & Pérez-Stable, E. J. COVID-19 and Racial/Ethnic  
317 Disparities. *JAMA* **323**, 2466-2467, doi:10.1001/jama.2020.8598 (2020).
- 318 32 Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality  
319 among Black Patients and White Patients with Covid-19. *New Engl J Med* **382**, 2534-2543,  
320 doi:10.1056/NEJMsa2011686 (2020).
- 321 33 Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary  
322 Report. *N Engl J Med*, doi:10.1056/NEJMoa2021436 (2020).
- 323
- 324

325 **Tables**

326

327 **Table 1. Odds ratios for COVID positivity by *HSD3B1* genotype among COVID-tested**


328 **members of the UK Biobank Caucasian cohort.**

Group	N (cases; controls)	regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
		odds ratio (95% confidence interval)	p-value	odds ratio (95% confidence interval)	p-value
<b>both sexes</b>	10,061	1.05	0.322	1.19	0.079
all ages	(1148; 8913)	(0.96 – 1.15)		(0.98 – 1.44)	
<b>male</b>	5042	0.99	0.859	1.13	0.397
all ages	(621; 4421)	(0.87 – 1.12)		(0.86 – 1.48)	
<b>female</b>	5019	1.12	0.106	1.26	0.102
all ages	(527; 4492)	(0.98 – 1.28)		(0.96 – 1.65)	
<b>both sexes</b>	4111	0.99	0.936	1.03	0.836
age < 70	(536; 3575)	(0.86 – 1.14)		(0.76 – 1.40)	
age ≥ 70	5950	1.08	0.206	1.30	0.038
	(612; 5338)	(0.96 – 1.23)		(1.01 – 1.68)	
<b>male</b>	1814	1.00	0.999	1.03	0.900
age < 70	(252; 1562)	(0.81 – 1.23)		(0.65 – 1.63)	
age ≥ 70	3228	0.98	0.832	1.20	0.297
	(369; 2859)	(0.83 – 1.16)		(0.85 – 1.69)	
<b>female</b>	2297	0.99	0.926	1.04	0.851
age < 70	(284; 2013)	(0.82 – 1.20)		(0.69 – 1.56)	
age ≥ 70	2722	1.24	0.025	1.49	0.037
	(243; 2479)	(1.03 – 1.50)		(1.02 – 2.16)	


329 Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI  
330 (regressions limited to one sex).

331


332 **Figures**  
333



334  
335 **Figure 1. Adrenal-permissive *HSD3B1* genotype leads to greater androgen synthesis and**  
336 **immune suppression.** Depending on genotype, *HSD3B1* codes for an enzyme 3 $\beta$ HSD1 that is  
337 either readily ubiquitinated and degraded (adrenal-restrictive form, left) or is resistant to  
338 ubiquitination and degradation (adrenal-permissive form, right) and as a result accumulates at  
339 higher levels in cells. The higher levels of the adrenal-permissive enzyme enable greater  
340 conversion of DHEA to downstream potent androgens at sufficient levels to suppress immune  
341 responses, whereas these levels are not reached with the adrenal-restrictive form. Created with  
342 BioRender.com.  
343



344  
345 **Figure 2. Older subjects, particularly older women, who are homozygous for the adrenal-**  
346 **permissive *HSD3B1*(1245C) allele have heightened COVID positivity.** Odds ratios and 95%  
347 confidence intervals for COVID positivity in subjects of CC genotype vs. other (AA or AC)  
348 genotypes in different age and sex breakdowns of the UK Biobank Caucasian cohort. (A) Subjects  
349 who tested positive for COVID vs. subjects who tested negative for COVID. For numbers of cases  
350 and controls in each group, see **Table 1**. (B) COVID-positive subjects vs. all other members of  
351 cohort. For numbers of cases and controls in each group, see **Table S1**. Results were adjusted for  
352 sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to  
353 one sex).  
354



355  
356 **Figure 3. CC genotype associates with higher COVID positivity in older women regardless**  
357 **of the lower cutoff age for inclusion in the analysis.** Odds ratios (thick line) and 95% confidence  
358 intervals (thin lines) for being COVID-positive in Caucasian women at least [cutoff age] years old  
359 with CC genotype vs. other genotypes (AA or AC), by cutoff age. For each year of age, the odds  
360 ratio and confidence interval in COVID-tested women that age or older were calculated. Note that  
361 the result at a lower cutoff age of 70 is the same as the “female, age  $\geq 70$ ” result in the right-hand  
362 side of **Table 1**.  
363

364 **Methods**

365 Analysis was performed on subjects from the UK Biobank, a long-term study tracking  
366 medical information of over 500,000 genotyped individuals. Genotyping was performed using the  
367 UK BiLEVE Axiom Array or UK Biobank Axiom Array by Applied Biosystems. Additional SNPs  
368 were imputed with the IMPUTE4 program using the Haplotype Reference Consortium, UK10K,  
369 and 1000 Genomes phase 3 panels as reference panels. Rs1047303 (i.e., *HSD3B1*(1245A/C)) was  
370 imputed with high accuracy (information score > 0.99).

371 Population structure and ancestry were assessed via principal component analysis on SNP  
372 data, and outliers were excluded. Final sample sizes for different ethnicities after quality control  
373 were 384,810 Caucasian, 7224 African, 7193 South Asian, and 1409 Chinese. The sample sizes  
374 for subjects with COVID test results available as of August 3, 2020, by ethnicity, were 10,061  
375 Caucasian, 300 African, 253 South Asian, and 31 Chinese. Due to inadequate sample sizes as well  
376 as lower *HSD3B1*(1245C) frequencies of other ethnicities (1245C frequencies in overall cohort by  
377 ethnicity: 0.323 Caucasian, 0.085 African, 0.193 South Asian, 0.074 Chinese), analyses reported  
378 in this study were limited to subjects of Caucasian ethnicity.

379 For analysis of mortality with COVID as a cause of death, death records from the UK  
380 Biobank were downloaded, and subjects with ICD10 codes U07.1 (i.e., laboratory-confirmed  
381 COVID) or U07.2 (i.e., clinically diagnosed COVID without laboratory confirmation) in a cause  
382 of death field were identified. For analysis of mortality among COVID-positive subjects, death  
383 records were cross referenced against COVID test results and subjects who died after having tested  
384 positive for COVID were identified.

385           Analyses were performed using R under RStudio. This study was approved by the NHS  
386 National Research Ethics Committee (REC ref 16/NW/0274) through the generic ethical approval  
387 for UK Biobank studies (approved UK Biobank application #44578).

388 **Data and materials availability:** Data are regulated by UK Biobank’s policies on access.

389

390

391

392

393 **Acknowledgments:**

394 **Funding:** This work was supported in part with grants from the National Cancer Institute  
395 (R01CA172382, R01CA190289, and R01CA236780) and the Prostate Cancer Foundation (to  
396 NS).

397 **Author contributions:** Jeffrey M. McManus: conceptualization, methodology, investigation,  
398 writing – original draft, visualization; Navin Sabharwal: methodology, investigation, data  
399 curation; Peter Bazeley: methodology, data curation; Nima Sharifi: conceptualization, writing –  
400 review & editing, supervision, funding acquisition

401 **Competing interests:** Cleveland Clinic has a patent on *HSD3BI* in prostate cancer.

402

403

404 **Extended Data**

405 **Table S1. Odds ratios for COVID positivity (COVID-positive vs. all other members of**  
 406 **cohort) by *HSD3B1* genotype in the UK Biobank Caucasian cohort.**

Group	n (cases; controls)	regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
		odds ratio (95% confidence interval)	p-value	odds ratio (95% confidence interval)	p-value
<b>both sexes</b>	384,810	1.03	0.535	1.14	0.156
all ages	(1148; 383,667)	(0.94 – 1.12)		(0.95 – 1.36)	
<b>male</b>	178,118	0.97	0.667	1.04	0.748
all ages	(621; 177,497)	(0.86 – 1.10)		(0.81 – 1.34)	
<b>female</b>	206,692	1.10	0.161	1.26	0.080
all ages	(527; 206,165)	(0.96 – 1.24)		(0.97 – 1.63)	
<b>both sexes</b>	187,714	0.99	0.854	0.96	0.801
age < 70	(536; 187,178)	(0.87 – 1.12)		(0.73 – 1.28)	
age ≥ 70	197,096	1.07	0.295	1.30	0.029
	(612; 196,484)	(0.95 – 1.20)		(1.03 – 1.65)	
<b>male</b>	83,980	0.97	0.778	0.90	0.623
age < 70	(252; 83,728)	(0.81 – 1.17)		(0.59 – 1.37)	
age ≥ 70	94,138	0.98	0.762	1.14	0.408
	(369; 93,769)	(0.84 – 1.14)		(0.83 – 1.57)	
<b>female</b>	103,734	1.00	0.988	1.02	0.909
age < 70	(284; 103,450)	(0.84 – 1.19)		(0.70 – 1.49)	
age ≥ 70	102,958	1.21	0.040	1.55	0.014
	(243; 102,715)	(1.01 – 1.46)		(1.09 – 2.20)	

407 Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI  
 408 (regressions limited to one sex).  
 409

410 **Table S2. Odds ratios for mortality with COVID as a cause of death by *HSD3B1* genotype**  
 411 **in the UK Biobank Caucasian cohort.**

Group	n (cases; controls)	regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
		odds ratio (95% confidence interval)	p-value	odds ratio (95% confidence interval)	p-value
both sexes all ages	384,810 (325; 384,485)	1.01 (0.85 – 1.19)	0.936	1.14 (0.82 – 1.61)	0.435
male all ages	178,118 (212; 177,906)	0.94 (0.76 – 1.15)	0.525	0.95 (0.61 – 1.49)	0.829
female all ages	206,692 (113; 206,579)	1.15 (0.88 – 1.51)	0.315	1.53 (0.91 – 2.56)	0.109
both sexes age ≥ 70	197,096 (281; 196,815)	0.97 (0.81 – 1.16)	0.743	1.19 (0.83 – 1.71)	0.339
male age ≥ 70	94,138 (185; 93,953)	0.90 (0.72 – 1.12)	0.335	0.99 (0.62 – 1.60)	0.974
female age ≥ 70	102,958 (96; 102,862)	1.12 (0.84 – 1.51)	0.439	1.60 (0.92 – 2.77)	0.096


412 Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI  
 413 (regressions limited to one sex).

414 **Table S3. Odds ratios for all-cause mortality by *HSD3B1* genotype among subjects who**  
 415 **tested COVID+ in the UK Biobank Caucasian cohort.**

Group	n (cases; controls)	regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
		odds ratio (95% confidence interval)	p-value	odds ratio (95% confidence interval)	p-value
both sexes all ages	1107 (220; 887)	1.03 (0.82 – 1.29)	0.786	1.10 (0.70 – 1.75)	0.674
male all ages	598 (147; 451)	0.97 (0.73 – 1.30)	0.845	0.92 (0.50 – 1.71)	0.802
female all ages	509 (73; 436)	1.13 (0.78 – 1.64)	0.508	1.38 (0.69 – 2.79)	0.365
both sexes age ≥ 70	596 (183; 413)	1.05 (0.82 – 1.35)	0.696	1.22 (0.73 – 2.02)	0.447
male age ≥ 70	361 (123; 238)	0.95 (0.69 – 1.30)	0.730	0.98 (0.50 – 1.93)	0.957
female age ≥ 70	235 (60; 175)	1.24 (0.83 – 1.87)	0.296	1.59 (0.74 – 3.41)	0.239

416 Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI  
 417 (regressions limited to one sex). Inclusion in analysis was restricted to subjects who tested  
 418 COVID+ prior to the most recent reported death (June 28, 2020) at the time analyses were  
 419 performed.

420



421  
422 **Figure S1. Effect of lower cutoff age on associations between CC genotype and COVID**  
423 **positivity for Caucasians of both sexes or of male sex.** Odds ratios (thick line) and 95%  
424 confidence intervals (thin lines) for being COVID-positive in men and women together (**A**) or men  
425 (**B**) at least [cutoff age] years old with CC genotype vs. AA or AC genotype, by cutoff age. For  
426 each year of age, the odds ratio and confidence interval in COVID-tested subjects that age or older  
427 were calculated. Note that the results at a cutoff age of 70 are the same as the “both sexes, age  $\geq$   
428 70” (**A**) or “male, age  $\geq$  70” (**B**) results in the right-hand side of **Table 1**.  
429